10/14/2014 2:15 PM EDT
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. It affects about 100,000 children and adults in the United States—and millions of people worldwide. New treatments are needed to prevent and treat its serious complications. That’s why the U.S. Food and Drug Administration is working with patients and stakeholders, including those from academia and the pharmaceutical industry, to develop new products.
FDA also has met with patients to learn more about their experiences with SCD and their views on existing treatments. Additional meetings are being planned.
Be a Seed for Change 
You must be logged in to post a comment.